Published in final edited form as:

J Perinat Med. 2009 ; 37(3): 218–231. doi:10.1515/JPM.2009.053.

VISFATIN IN HUMAN PREGNANCY: MATERNAL GESTATIONAL DIABETES VIS-À-VIS NEONATAL BIRTHWEIGHT

S. MAZAKI-TOVI^{1,2}, R. ROMERO^{1,3}, J. P. KUSANOVIC^{1,2}, E. VAISBUCH^{1,2}, O. EREZ^{1,2}, N. G. THAN¹, T. CHAIWORAPONGSA^{1,2}, C. L. NHAN-CHANG^{1,2}, P. PACORA¹, F. GOTSCH¹, L. YEO^{1,2}, S. S. EDWIN¹, S. S. HASSAN^{1,2}, and P. MITTAL^{1,2}

¹Perinatology Research Branch, Intramural Division, NICHD/NIH/DHHS, Hutzel Women's Hospital, Bethesda, MD, and Detroit, MI

²Department of Obstetrics and Gynecology, Wayne State University/Hutzel Women's Hospital, Detroit, MI

³Center for Molecular Medicine and Genetics, Wayne State University, Detroit, MI

Abstract

Objective—Adipose tissue dysfunction, characterized by dysregulation of adipokines production and/or secretion, has been implicated in the pathophysiology of type-2 diabetes mellitus, a metabolic complication closely related to gestational diabetes mellitus (GDM). Recently, an association between circulating maternal visfatin, a novel adipokine with metabolic and immunoregulatory properties, and impaired glucose metabolism as well as with altered fetal growth, has been proposed. The aims of this study were to determine whether there is an association between maternal plasma visfatin concentration, GDM, and a large-for-gestational-age (LGA) newborn.

Study design—This cross-sectional study, included pregnant women at term in the following groups: 1) normal pregnancy and an appropriate-for-gestational-age (AGA) neonate (n=54); 2) normal pregnancy and an LGA newborn (n=47); 3) GDM and an AGA newborn (n=56); 4) GDM and an LGA newborn (n=45). The study population was further stratified by first trimester BMI (<25 vs. ≥25 kg/m²). Maternal plasma visfatin concentration was determined by ELISA. Parametric and non-parametric statistics were used for analysis.

Results—1) Among women who delivered an AGA neonate, the median maternal plasma concentration of visfatin was higher in patients with GDM than in those with a normal pregnancy; 2) Among women with a normal pregnancy, those who delivered an LGA neonate had a higher median maternal plasma visfatin concentration than those who delivered an AGA neonate; 3) among patients with normal BMI, there were no significant differences in the median maternal plasma visfatin concentration between the four study groups; and 4) maternal GDM, as well as delivery of an LGA neonate were independently associated with a higher maternal plasma visfatin concentrations.

Conclusion—The linkage between increased maternal circulating visfatin and the presence of GDM or delivery of an LGA neonate supports the hypothesis that perturbation of adipokines homeostasis may play a role in the pathophysiology of GDM or excess fetal growth.

Keywords

Visfatin; gestational diabetes mellitus (GDM); large-for-gestational-age (LGA); appropriate-for-gestational-age (AGA); pre-B cell colony-enhancing factor (PBEF); adipokine; adipose tissue

Introduction

Pregnancy is a unique condition characterized by transient physiologic insulin resistance^{21;24;25;30–32;58;65;105;109;114;158;167;177} which progresses with advancing gestation and approaches that of non-pregnant patients with type-2 diabetes mellitus (DM).¹⁸ Teleologically, this physiological adaptation is aimed to facilitate delivery of nutrients to the fetus.^{104;165} The implicit paradigm that has been governed the understanding of the metabolic adaptation during pregnancy, was that insulin resistance should be attributed to the “diabetogenic” effect of placental hormones, such as human placental lactogen (hPL), estrogen, and progesterone. Indeed, both *in vivo* and *in vitro* studies support this view.^{11;13;41;90;91;159;166;169} However, during the last decade, with the recognition of adipose tissue as an active endocrine organ, an alternative paradigm for the pathogenesis of insulin resistance has been emerged.^{12;51;77;78;155;186;190} Indeed, a solid body of evidence support the central role of adipose tissue in the regulation of energy homeostasis as well as in metabolism and inflammation in pregnant and non-pregnant subjects.^{8;9;28;51;68;83;88;89;93;99;118;126;128;136;162–164;178;185;187;194}

Visfatin is a 52 kDa adipokine, which is preferentially produced by visceral adipose tissue^{63;82;174} and corresponds to the previously identified growth factor for early B cell, termed pre-B cell colony-enhancing factor (PBEF).^{86;124;149;170;198} Recently, the metabolic effects of visfatin have been highlighted. Indeed, *in vitro*, adipocytes exposure to glucose increased their secretion of this adipokine.⁷³ Moreover, visfatin exerts insulin-like activity as a growth factor for osteoblasts.¹⁹⁵ Plasma concentrations of visfatin are higher in patients with type-2 DM^{36;53;116;171} as well as in obesity^{19;35;55;56;72;87;171;203} than in normal subjects, and have a positive correlation with body mass index (BMI)^{19;35;113;171} and waist-to-hip ratio.³⁶ Collectively, these data suggest that visfatin has a role in the physiology and pathophysiology of glucose metabolism.

Only handful of studies have addressed the maternal concentration of visfatin in human pregnancy.^{34;50;52;71;101;112;120;121;125} Furthermore, data regarding circulating maternal concentrations of visfatin in patients with gestational diabetes mellitus (GDM) are both scarce and conflicting. Indeed, maternal visfatin concentrations (plasma/serum) were reported to be higher^{101;112} and lower^{34;71} in patients with GDM than in normal pregnant women. Interestingly, maternal plasma concentrations of visfatin are significantly elevated in patients with fetal growth restriction than in those with an appropriate-for-gestational-age (AGA) neonate. Thus, the aims of this study were to determine whether there is an association between maternal plasma visfatin concentration, GDM, and a large-for-gestational-age (LGA) newborn.

Materials and Methods

A cross-sectional study was conducted by searching our clinical database and bank of biological samples, and included pregnant women at term in the following groups: 1) normal pregnant women who delivered an AGA newborn (n=54); 2) normal pregnant women who delivered an LGA newborn (n=47); 3) women with GDM who delivered an AGA newborn (n=56); and 4) women with GDM who delivered an LGA newborn (n=45). Women with multiple pregnancies or fetal congenital anomalies were excluded.

All women provided written informed consent prior to the collection of maternal blood samples. The utilization of samples for research purposes was approved by the institutional review boards of Wayne State University, Sotero del Rio Hospital and the *Eunice Kennedy Shriver* National Institute of Child Health and Human Development (NICHD/NIH/DHHS). Many of these samples have been previously employed to study the biology of inflammation, hemostasis, and growth factor concentrations in normal pregnant women, and those with pregnancy complications.

Definitions

The inclusion criteria for normal pregnancy were: (1) no medical, obstetrical or surgical complications; (2) intact membranes; (3) delivery of a term neonate (>37 weeks) with a birth weight above the 10th percentile;⁷ and (4) a normal oral 75-g oral glucose tolerance test (OGTT) between 24–28 weeks of gestation based on World Health Organization (WHO) criteria.^{3,6}

All women underwent a 75-g OGTT between 24 and 28 weeks of gestation. Diagnosis of GDM was based on the World Health Organization (WHO) criteria of fasting plasma glucose 126 mg/dl (7.0 mmol/L) or plasma glucose 140 mg/dl (7.8 mmol/L) two hours after the 75-g OGTT.^{3,6} GDM patients were treated with diet. LGA newborn was defined as an infant with birth weight above the 90th percentile.^{7,69} The first trimester BMI was calculated according to the following formula: weight (kg)/height (m)² and patients were classified according to the definitions of the WHO.² A normal weight was defined as BMI between 18.5 and 25 kg/m² and overweight/obese as BMI ≥ 24.9 kg/m².

Sample collection

Maternal blood samples were collected at clinical visit. The gestational ages of sample collection were 37 weeks for all women included in the study. Blood was centrifuged at 1300 × g for 10 minutes at 4°C. The plasma obtained was stored at –80°C until analysis.

Human Visfatin C-terminal immunoassay

Concentrations of visfatin in maternal plasma were determined using specific and sensitive enzyme immunoassays purchased from Phoenix Pharmaceuticals, Inc (Belmont, CA, USA). Visfatin C-terminal assays were validated in our laboratory for using human plasma prior to the conduction of this study. Validation included spike and recovery experiments, which produced parallel curves indicating that maternal plasma matrix constituents did not interfere with antigen-antibody binding in this assay system. Visfatin enzyme immunoassays are based on the principle of competitive binding and were conducted according to recommendation of the manufacturer. Briefly, assay plates are pre-coated with a secondary antibody and the non-specific binding sites have been blocked. Standards and samples were incubated in the assay plates along with primary antiserum and biotinylated peptide. The secondary antibody in the assay plates bound to the Fc fragment of the primary antibody whose Fab fragment competitively bound with both the biotinylated peptide and peptide standard or targeted peptide in the samples. Following incubation, the assay plates were repeatedly washed to remove unbound materials and incubated with a streptavidin-horseradish peroxidase (SA-HRP) solution. Following incubation, unbound enzyme conjugate was removed by repeated washing and a substrate solution was added to the wells of the assay plates and color developed in proportion to the amount of biotinylated peptide-SA-HRP complex but inversely proportional to the amount of peptide in the standard solutions or the samples. Color development was stopped with the addition of an acid solution and the intensity of color was read using a programmable spectrophotometer (SpectraMax M2, Molecular Devices, Sunnyvale, CA, USA). Maternal plasma concentrations of visfatin C were determined by interpolation from individual standard

curves composed of human visfatin peptide. The calculated inter- and intra-assay coefficients of variation for Visfatin C-terminal immunoassays in our laboratory were 5.3% and 2.4%, respectively. The sensitivity was calculated to be 0.04 ng/mL.

Statistical analysis

The Shapiro–Wilk and Kolmogorov–Smirnov tests were used to test for normal distribution of the data. Data are presented as median and interquartile range (IQR). Non-parametric methods were used to perform the statistical analysis for parameters which were not normally distributed and comparisons among groups were performed using the Kruskal–Wallis test with post hoc test by Mann–Whitney U test. Parametric tests were used for analysis of those parameters that were normally distributed and the comparisons among groups were performed using one-way ANOVA with Bonferroni adjustment for the calculated p-value in order to maintain the significance level at 0.05. Multiple linear regression analysis was used to determine which factors were significantly and independently correlated with maternal plasma visfatin concentration (after log transformation). The following parameters were included in the model: maternal age, maternal BMI, gestational age at blood collection, GDM and LGA. The statistical package employed was SPSS 14 (SPSS Inc., Chicago, IL, USA). A p-value of <0.05 was considered statistically significant.

Results

The clinical and demographic characteristics of the study groups are presented in Table 1. Patients with GDM and an AGA neonate ($p=0.01$) or those with GDM and an LGA neonate ($p<0.01$) had a higher median maternal age than normal pregnant women with an AGA neonate.

Maternal plasma visfatin concentration in women with a normal pregnancy

Visfatin was detected in the plasma of all subjects. There was a significant difference in the median maternal plasma visfatin concentration among the groups ($p=0.006$, Kruskal–Wallis).

Among women with a normal pregnancy, those with an LGA neonate had a higher median maternal plasma visfatin concentration than those with an AGA neonate (LGA 19.5 ng/mL, IQR 16.2–22.0 vs. AGA 16.6 ng/mL, IQR 12.2–19.7, $p<0.01$; Figure 1). Among women who delivered an AGA neonate, the median maternal plasma concentration was higher in patients with GDM than those with a normal pregnancy (GDM: 18.3 ng/mL, IQR 15.9–22.0 vs. normal pregnancy 16.6 ng/mL, IQR 12.2–19.7, $p=0.01$; Figure 1).

Maternal plasma visfatin concentration in women with gestational diabetes mellitus

Patients with GDM who delivered an LGA neonate had a higher median maternal plasma visfatin concentration than those with a normal pregnancy and an AGA neonate (GDM +LGA 19.7 ng/mL, IQR: 16.2–23.1 vs. normal pregnancy+AGA 16.6 ng/mL, IQR 12.2–19.7, $p<0.01$; Figure 1). There were no significant differences in the median maternal plasma visfatin concentration in women with a normal pregnancy and an LGA neonate and patients with GDM who delivered either an LGA or AGA neonate ($p=0.9$ and $p=0.3$, respectively; Figure 1).

Patients with GDM who delivered an AGA ($p=0.002$) or an LGA neonate ($p<0.001$) had a higher median maternal BMI than those with a normal pregnancy and an AGA neonate. Similarly, patients with GDM and an LGA neonate ($p=0.02$) had a higher median maternal BMI than those with a normal pregnancy and an LGA neonate (Table 1). The rate of

overweight/obese women was higher in patients with GDM who delivered an LGA neonate than in those with a normal pregnancy who delivered an AGA neonate ($p=0.03$).

Maternal plasma visfatin concentration in normal and overweight/obese pregnant women with a normal pregnancy

—Among overweight/obese women with a normal pregnancy, those with an LGA neonate had a higher median maternal plasma visfatin concentration than those with an AGA neonate (LGA: 18.8 ng/mL, IQR: 16.5–22.4 vs. normal AGA 13.7 ng/mL, IQR 10.4–19.6, $p=0.003$; Figure 2); however, such difference was not detected among women with a normal weight ($p=0.12$).

Maternal plasma visfatin concentration in normal and overweight/obese pregnant women with gestational diabetes mellitus

—Overweight/obese patients with GDM, either with an AGA (17.9 ng/mL, IQR: 15.4–22.3) or an LGA neonate (18.1 ng/mL, IQR: 15.0–22.4), had a higher median maternal plasma visfatin concentration than overweight/obese women with a normal pregnancy who delivered an AGA neonate (13.7 ng/mL, IQR 10.4–19.6; $p=0.01$ and $p=0.03$, respectively; Figure 2); however, such differences were not observed when normal weight patients with GDM, either with an AGA or an LGA neonate, were compared to normal weight women with a normal pregnancy and an LGA neonate ($p=0.96$ and $p=0.29$, respectively). In addition, among normal weight women with GDM, there was no significant difference in the median maternal plasma visfatin concentration between those who delivered an AGA and those who delivered an LGA neonate ($p=0.43$).

In order to further study the association between maternal plasma visfatin concentration and possible confounding factors, a multiple linear regression analysis was performed. Gestational diabetes mellitus ($p=0.03$) and the delivery of an LGA neonate ($p=0.008$) were independently associated with higher maternal plasma visfatin concentrations after correction for first trimester maternal BMI, maternal age, and gestational age at blood collection (Table 2).

Discussion

Principal findings of the study

1) Among women who delivered an AGA neonate, the median maternal plasma concentration of visfatin was higher in patients with GDM than in those with a normal pregnancy; 2) among women with a normal pregnancy, those who delivered an LGA neonate had a higher median maternal plasma visfatin concentration than those who delivered an AGA neonate; 3) among patients with normal BMI, there were no significant differences in the median maternal plasma visfatin concentration between the four study groups; and 4) GDM, as well as delivery of an LGA neonate were independently associated with a higher maternal plasma visfatin concentrations.

Visfatin is a novel adipokine with metabolic and immunoregulatory properties

—Visfatin, a highly conserved 52 kDa molecule, was originally cloned in 1994 from human peripheral blood lymphocytes,¹⁷⁰ and its homologous proteins have been reported in bacteria,¹²³ invertebrate,¹³⁸ fish⁶¹ and mammals.^{94;124;127;142;143;148–151;170;198} This adipokine enhances the effect of IL-7 and stem cell factor on pre-B-cell colony formation, hence it was named pre-B-cell enhancing factor (PBEF).¹⁷⁰ Recently, visfatin/PBEF was reported to be produced by adipose tissue,^{19;38;60;75;173;174} thus included in the growing family of adipokines. While preferentially produced by visceral fat depot,^{82;174;184} the expression of visfatin is not limited to adipose tissue. Indeed, it can be expressed in placenta,

fetal membranes,^{95;124;142;143;148–151} myometrium,⁴⁸ bone marrow, liver, muscle,¹⁷⁰ heart, lung, kidney,¹⁷⁰ macrophages,⁴³ and neutrophils.^{86;170;198}

The physiologic role of visfatin in humans has not been fully elucidated; however, it has been proposed that this adipokine has a regulatory role in glucose metabolism and inflammation. The following features about visfatin suggest that this protein have a regulatory role in glucose homeostasis: 1) *in vitro*, adipocytes secrete visfatin in response to glucose exposure;⁷³ 2) administration of glucose to human subjects results in increase circulating visfatin concentration;⁷³ 3) obesity is associated with increased circulating visfatin concentration,^{19;35;55;56;72;87;171;203} and plasma concentrations of this adipokine are positively correlated with BMI^{19;35;113;171} and waist-to-hip ratio;³⁶ 4) consistent with the aforementioned reports, serum concentration of visfatin in humans are positively correlated with the amount of intra-visceral fat as determined by computerized tomography scan;¹⁷¹ 5) plasma concentrations of visfatin are higher in patients with type-2 DM^{36;53;116;171} or metabolic syndrome^{55;56} than in normal subjects; and 6) a visfatin promoter polymorphism is associated with a susceptibility to type-2 DM.²⁰⁴

Evidence in support of the immunoregulatory effects of visfatin includes: 1) the production of proinflammatory cytokines (e.g. IL-6, TNF- α , IL-1 β) by human monocytes, is up-regulated by visfatin in a dose dependent manner;¹³⁷ 2) the expression of visfatin is increased following exposure to proinflammatory mediators such as TNF- α (in monocytes,⁴³ macrophages⁸⁴ and neutrophils⁸⁶), IL-6 (synovial¹⁴⁴ and amniotic epithelial cells¹⁴⁸) and IL-8 and granulocyte/macrophage colony stimulating factor (in neutrophils⁸⁶); 3) visfatin expression is increased in cells retrieved by bronchoalveolar lavage from patients with acute lung injury¹⁹⁸ and from lung tissue of animals models of acute lung injury;¹⁹⁹ similarly, its expression increases in neutrophils from septic patients;⁸⁶ 4) polymorphisms in the visfatin gene are associated with an increased (*-1001G*) or decreased (*-1543T*) risk of developing ARDS in septic shock patients than wild-type homozygotes;¹⁰ and 5) patients with chronic inflammatory disorders such as inflammatory bowel disease¹³⁷ and rheumatoid arthritis¹⁵³ have higher circulating visfatin than normal subjects.

Adipose tissue dysfunction: a novel mechanism of disease for gestational diabetes mellitus

—Incapacity of the adipose tissue to meet the metabolic demands has been suggested as a putative mechanism of disease for type-2 DM.^{67;106} According to this hypothesis, one of the core components of adipose tissue failure is impaired production and/or secretion of adipokines. Indeed, several lines of evidence support a causality linkage between dysregulation of adipokines and type-2 DM: 1) mice deficient in adiponectin,^{103;119;140;196} leptin,^{39;80} or TNF- α ¹⁸⁹ have insulin resistance; in addition, the administration of leptin,^{26;74;156} adiponectin^{16;59;196} or neutralization of resistin¹⁸¹ corrects insulin resistance in obese and diabetic mice; 2) polymorphisms at the locus of adiponectin,^{57;70;76;81;110;132;139;182} resistin,^{131;152} visfatin,²⁰⁴ or leptin receptor¹⁶⁸ are associated with insulin resistance and type-2 DM; and 3) patients with type-2 DM have a higher plasma concentrations of resistin,^{62;129;202} TNF- α ,^{44;135} RBP-4^{37;197}, CRP^{54;160} and a lower concentrations of adiponectin,^{79;97;160;191} than normal subjects.

Gestational diabetes mellitus is defined as a carbohydrate intolerance of varying severity, with onset, or first recognition during pregnancy.^{1;27;64;65;134;147} This adverse metabolic state affects 1–10% of all pregnancies,^{4;5;14;22;27;29;45;65;66;109;147} and is associated with maternal, fetal and neonatal complications.^{5;15;17;20;23;33;40;42;45;47;85;96;100;133;141;145;146;157;172;179;180} Similarly to type-2 DM, adipose tissue failure, characterized by altered maternal circulating concentration of adipokines (e.g. TNF- α ,^{49;78;107;154;161;186;190;201} CRP,¹²⁸ leptin^{9;93;99;128} and adiponectin^{9;98;162;185;192;194}), has been implicated in the pathophysiology of GDM.

Indeed, during pregnancy, maternal serum concentrations of several adipokines are correlated with clinical indices of insulin resistance (e.g HOMA).^{28;99;118;128;163} Moreover, women with low circulating adiponectin concentrations¹⁹² or high circulating concentrations of CRP^{176;193} during early pregnancy are more likely to develop GDM than those with normal concentrations of these adipokines. Collectively, these findings suggest that adipokines play a role in the pathophysiology of GDM.

Visfatin in human pregnancy—There are only few reports regarding circulating visfatin concentrations in pregnant women.^{34;50;52;71;101;112;120;121;125} Mastorakos et al.¹²⁵ conducted a longitudinal study in which maternal serum visfatin concentrations were determined in 80 normal pregnant women at 10–12, 24–26 and 34–36 weeks of gestation. During the first trimester, visfatin concentrations were negatively correlated with percentage of fat mass and hip circumference. However, during the second and third trimesters, serum concentrations of this adipokine were not correlated with these surrogate markers of adipose tissue quantity. The authors suggested that the progressive increase in insulin resistance with advancing gestation can be compensated by a sustained increase of visfatin secretion by the adipose tissue.¹²⁵ Fasshauer et al.⁵⁰ reported that during the third-trimester, women with intrauterine growth restriction (n=18) had a higher mean maternal plasma visfatin concentration than those with an AGA neonate (n=10). The same group reported that patients with preeclampsia in the third-trimester (n=15) had a higher mean maternal serum visfatin concentration than normal pregnant women (n=20)⁵² and that maternal circulating visfatin was negatively correlated with HOMA-IR, but not with maternal age or BMI.⁵²

The association between maternal plasma visfatin concentrations and gestational diabetes mellitus—We report herein that GDM is independently associated with increased maternal plasma visfatin concentrations. Studies regarding maternal circulating visfatin in patients with GDM are scant and inconsistent: both increased^{101;112} and decreased^{34;71} maternal visfatin concentrations were reported. Our findings are in agreement with those of Krzyanowska et al.¹⁰¹ who reported a higher maternal circulating visfatin in 64 patients with GDM than in 30, mostly overweight, normal pregnant women at 28–30 weeks of gestation. Subsequently, Lewandowski et al.¹¹² reported higher maternal visfatin concentrations in 16 patients with GDM compared to 20 normal pregnant women at 28 weeks of gestation. In contrast, Chan et al.³⁴ demonstrated that patients with GDM (n=20) in the late second trimester have a lower mean visfatin serum concentration than normal pregnant women (n=20). Haider et al.⁷¹ reported similar results in 10 patients with GDM and 10 aged-matched controls at the same gestational age (24–28 weeks). Differences in study design may contribute to explain the differences among studies. In particular, the number of subjects, gestational age at enrolment, differences in BMI and neonatal birth weights, differ between the studies.

The association between maternal plasma visfatin concentrations and neonatal birthweight—The independent association between the delivery of an LGA neonate and elevated maternal plasma visfatin concentrations is a novel finding. Previous reports have underscored the association between fetal growth restriction (FGR) and increased maternal circulating visfatin. Fasshauer et al.⁵⁰ reported that mean plasma maternal visfatin in the third trimester is higher in patients with FGR than those with an AGA newborn. This finding was corroborated by Malamitsi-Puchner et al.¹²⁰ Of interest, in the latter study, cord blood visfatin concentrations did not differ between SGA and AGA neonates.¹²⁰ The same group¹²¹ reported that among patients with a normal pregnancy and an AGA neonate, the mean cord blood visfatin concentration was similar and positively correlated with the mean maternal visfatin concentration; furthermore, the mean cord blood visfatin concentration was positively correlated with neonatal birthweight. Based on these

findings, the authors proposed that a passive transplacental transfer of visfatin is probable.^{120;121} López-Bermejo et al.¹¹⁷ reported a negative association between cord blood visfatin concentrations and indices of fetal size only in mothers who smoked, indicating that cord blood visfatin concentrations may be, in part, under the regulation of maternal factors. Taken together, these findings suggest that visfatin have a role in the metabolic crosstalk between maternal and fetal compartments. The strong association reported herein, between the delivery of an LGA neonate and elevated maternal plasma visfatin concentrations in mothers with and without GDM further support this hypothesis.

Visfatin concentrations in GDM and LGA neonate: maternal metabolic status vis-à-vis neonatal birthweight—Several explanations can account for the association of increased maternal plasma visfatin concentration and GDM or the delivery of an LGA neonate:

1. *Insulin resistance and impaired glucose metabolism in women with GDM and/or LGA neonate:* Insulin resistance is accompanied by increased visfatin production and/or secretion. Indeed, polymorphisms in the visfatin gene²⁰⁴ are associated with insulin resistance and type-2 DM. *In vivo* clamp studies in humans demonstrated that hyperglycemia increases circulating visfatin concentrations.⁷³ Moreover, circulating visfatin concentrations in patients with type-2 DM are higher than in normal subjects.^{36;53;171} Given the insulin-mimic effect of visfatin, it has been proposed that the increased concentrations of this hormone in the context of insulin resistance, reflect a compensatory mechanism aimed at ameliorating the functional consequences of insulin deficiency.¹¹⁶ Collectively, these reports suggest an association between insulin resistance and elevated visfatin. This explanation can also be applicable, in part, to women with an LGA neonate and without GDM since minor abnormalities of glucose metabolism, even in the absence GDM, have been implicated in patients with neonatal overgrowth.^{92;108;111;115;130;200}
2. *. Overdistention of fetal membranes in patients with an LGA neonate:* *In vitro* studies have established a causality between stretching of human fetal membranes and increased expression, production, and secretion of visfatin.^{95;142;143;149;150} Indeed, the visfatin gene is up-regulated in response to stretching of human fetal membranes.^{142;143} Moreover, visfatin has been shown to be secreted from amniotic epithelial-like cell line.¹⁵⁰ Recently, it has been demonstrated that both expression and secretion of visfatin increases after prolonged stretching of the fetal membranes.⁹⁵ Consistently, an increased immuno-staining for visfatin was demonstrated in the amnion of twins and triplets.⁹⁵ Thus, it is tempting to speculate that the increased maternal plasma visfatin concentrations are derived, in part, from the stretched fetal membranes of women with LGA fetuses. In addition, expression of visfatin in human placenta have been reported;¹⁷⁰ thus, an increased secretion of visfatin from larger placentas of LGA fetuses can also account for our findings.

Collectively, transplacental transport, increased placental mass, and overdistention of fetal membranes may account for the increase in maternal plasma visfatin concentrations in pregnant women with an LGA neonate.

Disparity in circulating maternal visfatin between normal and overweight/obese pregnant women - the role of maternal metabolic state and neonatal weight—As opposed to overweight/obese pregnant women, those with a normal BMI had a comparable median maternal visfatin concentration, regardless of their metabolic state (GDM) or neonatal birthweight. Consistent with our findings, Tsiotra et al.¹⁸⁸ reported that visfatin mRNA expression from human peripheral monocyte-enriched mononuclear cells is

significantly elevated in type-2 diabetic women, compared to healthy control women, independently of the presence of overweight/obesity.

The association between circulating visfatin and overweight/obesity is still under debate. Several studies argued in favor of this association: serum visfatin concentration correlates with the amount of visceral fat depot,¹⁷¹ waist-to-hip ratio,³⁶ and BMI.^{19;35;113;171} However, these reports were challenged by other investigators who failed to find a positive correlation between circulating visfatin and either visceral fat mass¹⁹ or BMI.^{36;46;50;53;87;102;122;175;183;203} Currently, the exact physiologic and pathophysiologic role of visfatin is not fully elucidated, as reflected from this inconsistency in the literature. In the present study, first trimester BMI was not independently associated with maternal plasma visfatin concentrations after correction for confounding factors. Thus, a cause and effect relationship between BMI and maternal circulating visfatin concentrations data can not be discern. However, we were able to extend the abovementioned observations by demonstrating that the similarity between circulating maternal visfatin in normal and overweight women is unvaried even in the presence of GDM and/or LGA neonate.

Conclusion

The linkage between increased maternal circulating visfatin and the presence of GDM or delivery of an LGA neonate support the hypothesis that perturbation of adipokines homeostasis plays a role in the pathophysiology of GDM and excess fetal growth.

Acknowledgments

Supported by the Intramural Research Program of the Eunice Kennedy Shriver National Institute of Child Health and Human Development, NIH, DHHS.

Reference List

1. National Diabetes Data Group. Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. *Diabetes*. 1979; 28:1039–57. [PubMed: 510803]
2. Diet, nutrition and the prevention of chronic diseases. World Health Organ Tech Rep Ser. 2003; 916:i–149. backcover. [PubMed: 12768890]
3. Report of a WHO Study Group. Prevention of diabetes mellitus. World Health Organ Tech Rep Ser. 1994; 844:1–100. [PubMed: 7941615]
4. Supplement 1. American Diabetes Association: clinical practice recommendations 2000. *Diabetes Care*. 2000; 23 (Suppl 1):S1–116. [PubMed: 10859117]
5. ACOG Practice Bulletin. Clinical management guidelines for obstetrician-gynecologists. Number 30, September 2001 (replaces Technical Bulletin Number 200, December 1994). Gestational diabetes. *Obstet Gynecol*. 2001; 98:525–38. [PubMed: 11547793]
6. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. *Diabet Med*. 1998; 15:539–53. [PubMed: 9686693]
7. Alexander GR, Himes JH, Kaufman RB, Mor J, Kogan M. A United States national reference for fetal growth. *Obstet Gynecol*. 1996; 87:163–68. [PubMed: 8559516]
8. Altinova AE, Toruner F, Bozkurt N, Bukan N, Karakoc A, Yetkin I, et al. Circulating concentrations of adiponectin and tumor necrosis factor-alpha in gestational diabetes mellitus. *Gynecol Endocrinol*. 2007; 23:161–65. [PubMed: 17454170]
9. Ategbro JM, Grissa O, Yessoufou A, Hichami A, Dramane KL, Moutairou K, et al. Modulation of adipokines and cytokines in gestational diabetes and macrosomia. *J Clin Endocrinol Metab*. 2006; 91:4137–43. [PubMed: 16849405]

10. Bajwa EK, Yu CL, Gong MN, Thompson BT, Christiani DC. Pre-B-cell colony-enhancing factor gene polymorphisms and risk of acute respiratory distress syndrome. *Crit Care Med.* 2007; 35:1290–95. [PubMed: 17414088]
11. Barbour LA, Shao J, Qiao L, Pulawa LK, Jensen DR, Bartke A, et al. Human placental growth hormone causes severe insulin resistance in transgenic mice. *Am J Obstet Gynecol.* 2002; 186:512–17. [PubMed: 11904616]
12. Barzilai N, Gupta G. Interaction between aging and syndrome X: new insights on the pathophysiology of fat distribution. *Ann N Y Acad Sci.* 1999; 892:58–72. [PubMed: 10842652]
13. Beck P. Progestin enhancement of the plasma insulin response to glucose in Rhesus monkeys. *Diabetes.* 1969; 18:146–52. [PubMed: 4974771]
14. Ben-Haroush A, Yogev Y, Hod M. Epidemiology of gestational diabetes mellitus and its association with Type 2 diabetes. *Diabet Med.* 2004; 21:103–13. [PubMed: 14984444]
15. Benjamin E, Winters D, Mayfield J, Gohdes D. Diabetes in pregnancy in Zuni Indian women. Prevalence and subsequent development of clinical diabetes after gestational diabetes. *Diabetes Care.* 1993; 16:1231–35. [PubMed: 8404425]
16. Berg AH, Combs TP, Scherer PE. ACRP30/adiponectin: an adipokine regulating glucose and lipid metabolism. *Trends Endocrinol Metab.* 2002; 13:84–89. [PubMed: 11854024]
17. Berger H, Crane J, Farine D, Armson A, De La RS, Keenan-Lindsay L, et al. Screening for gestational diabetes mellitus. *J Obstet Gynaecol Can.* 2002; 24:894–912. [PubMed: 12417905]
18. Bergman RN. Lilly lecture 1989. Toward physiological understanding of glucose tolerance. Minimal-model approach. *Diabetes.* 1989; 38:1512–27. [PubMed: 2684710]
19. Berndt J, Kloting N, Kralisch S, Kovacs P, Fasshauer M, Schon MR, et al. Plasma visfatin concentrations and fat depot-specific mRNA expression in humans. *Diabetes.* 2005; 54:2911–16. [PubMed: 16186392]
20. Brody SC, Harris R, Lohr K. Screening for gestational diabetes: a summary of the evidence for the U.S. Preventive Services Task Force. *Obstet Gynecol.* 2003; 101:380–92. [PubMed: 12576264]
21. Buchanan TA, Metzger BE, Freinkel N, Bergman RN. Insulin sensitivity and B-cell responsiveness to glucose during late pregnancy in lean and moderately obese women with normal glucose tolerance or mild gestational diabetes. *Am J Obstet Gynecol.* 1990; 162:1008–14. [PubMed: 2183610]
22. Buchanan TA, Xiang AH. Gestational diabetes mellitus. *J Clin Invest.* 2005; 115:485–91. [PubMed: 15765129]
23. Buchanan TA, Xiang AH, Kjos SL, Trigo E, Lee WP, Peters RK. Antepartum predictors of the development of type 2 diabetes in Latino women 11–26 months after pregnancies complicated by gestational diabetes. *Diabetes.* 1999; 48:2430–36. [PubMed: 10580433]
24. BURT RL. Peripheral utilization of glucose in pregnancy. III. Insulin tolerance. *Obstet Gynecol.* 1956; 7:658–64. [PubMed: 13322368]
25. Butte NF. Carbohydrate and lipid metabolism in pregnancy: normal compared with gestational diabetes mellitus. *Am J Clin Nutr.* 2000; 71:1256S–61S. [PubMed: 10799399]
26. Campfield LA, Smith FJ, Guisez Y, Devos R, Burn P. Recombinant mouse OB protein: evidence for a peripheral signal linking adiposity and central neural networks. *Science.* 1995; 269:546–49. [PubMed: 7624778]
27. Carpenter MW, Coustan DR. Criteria for screening tests for gestational diabetes. *Am J Obstet Gynecol.* 1982; 144:768–73. [PubMed: 7148898]
28. Catalano PM, Hoegh M, Minium J, Huston-Presley L, Bernard S, Kalhan S, et al. Adiponectin in human pregnancy: implications for regulation of glucose and lipid metabolism. *Diabetologia.* 2006; 49:1677–85. [PubMed: 16752186]
29. Catalano PM, Kirwan JP. Clinical utility and approaches for estimating insulin sensitivity in pregnancy. *Semin Perinatol.* 2002; 26:181–89. [PubMed: 12099307]
30. Catalano PM, Roman-Drago NM, Amini SB, Sims EA. Longitudinal changes in body composition and energy balance in lean women with normal and abnormal glucose tolerance during pregnancy. *Am J Obstet Gynecol.* 1998; 179:156–65. [PubMed: 9704782]

31. Catalano PM, Tyzbir ED, Roman NM, Amini SB, Sims EA. Longitudinal changes in insulin release and insulin resistance in nonobese pregnant women. *Am J Obstet Gynecol.* 1991; 165:1667–72. [PubMed: 1750458]
32. Catalano PM, Tyzbir ED, Wolfe RR, Calles J, Roman NM, Amini SB, et al. Carbohydrate metabolism during pregnancy in control subjects and women with gestational diabetes. *Am J Physiol.* 1993; 264:E60–E67. [PubMed: 8430789]
33. Catalano PM, Vargo KM, Bernstein IM, Amini SB. Incidence and risk factors associated with abnormal postpartum glucose tolerance in women with gestational diabetes. *Am J Obstet Gynecol.* 1991; 165:914–19. [PubMed: 1951553]
34. Chan TF, Chen YL, Lee CH, Chou FH, Wu LC, Jong SB, et al. Decreased plasma visfatin concentrations in women with gestational diabetes mellitus. *J Soc Gynecol Investig.* 2006; 13:364–67.
35. Chan TF, Chenb Sc YL, Chen HH, Lee CH, Jong SB, Tsai EM. Increased plasma visfatin concentrations in women with polycystic ovary syndrome. *Fertil Steril.* 2007; 88:401–405. [PubMed: 17335820]
36. Chen MP, Chung FM, Chang DM, Tsai JC, Huang HF, Shin SJ, et al. Elevated plasma level of visfatin/pre-B cell colony-enhancing factor in patients with type 2 diabetes mellitus. *J Clin Endocrinol Metab.* 2006; 91:295–99. [PubMed: 16234302]
37. Cho YM, Youn BS, Lee H, Lee N, Min SS, Kwak SH, et al. Plasma retinol-binding protein-4 concentrations are elevated in human subjects with impaired glucose tolerance and type 2 diabetes. *Diabetes Care.* 2006; 29:2457–61. [PubMed: 17065684]
38. Choi KC, Ryu OH, Lee KW, Kim HY, Seo JA, Kim SG, et al. Effect of PPAR-alpha and -gamma agonist on the expression of visfatin, adiponectin, and TNF-alpha in visceral fat of OLETF rats. *Biochem Biophys Res Commun.* 2005; 336:747–53. [PubMed: 16157299]
39. Coleman DL. Diabetes-obesity syndromes in mice. *Diabetes.* 1982; 31:1–6. [PubMed: 7160533]
40. Conway DL, Langer O. Effects of new criteria for type 2 diabetes on the rate of postpartum glucose intolerance in women with gestational diabetes. *Am J Obstet Gynecol.* 1999; 181:610–14. [PubMed: 10486471]
41. Costrini NV, Kalkhoff RK. Relative effects of pregnancy, estradiol, and progesterone on plasma insulin and pancreatic islet insulin secretion. *J Clin Invest.* 1971; 50:992–99. [PubMed: 4928265]
42. Coustan DR, Carpenter MW, O'Sullivan PS, Carr SR. Gestational diabetes: predictors of subsequent disordered glucose metabolism. *Am J Obstet Gynecol.* 1993; 168:1139–44. [PubMed: 8475959]
43. Dahl TB, Yndestad A, Skjelland M, Oie E, Dahl A, Michelsen A, et al. Increased expression of visfatin in macrophages of human unstable carotid and coronary atherosclerosis: possible role in inflammation and plaque destabilization. *Circulation.* 2007; 115:972–80. [PubMed: 17283255]
44. Daimon M, Oizumi T, Saitoh T, Kameda W, Hirata A, Yamaguchi H, et al. Decreased serum levels of adiponectin are a risk factor for the progression to type 2 diabetes in the Japanese Population: the Funagata study. *Diabetes Care.* 2003; 26:2015–20. [PubMed: 12832305]
45. Dang K, Homko C, Reece EA. Factors associated with fetal macrosomia in offspring of gestational diabetic women. *J Matern Fetal Med.* 2000; 9:114–17. [PubMed: 10902825]
46. Dogru T, Sonmez A, Tasci I, Bozoglu E, Yilmaz MI, Genc H, et al. Plasma visfatin levels in patients with newly diagnosed and untreated type 2 diabetes mellitus and impaired glucose tolerance. *Diabetes Res Clin Pract.* 2007; 76:24–29. [PubMed: 16956691]
47. Ecker JL, Greenberg JA, Norwitz ER, Nadel AS, Repke JT. Birth weight as a predictor of brachial plexus injury. *Obstet Gynecol.* 1997; 89:643–47. [PubMed: 9166293]
48. Esplin MS, Fausett MB, Peltier MR, Hamblin S, Silver RM, Branch DW, et al. The use of cDNA microarray to identify differentially expressed labor-associated genes within the human myometrium during labor. *Am J Obstet Gynecol.* 2005; 193:404–13. [PubMed: 16098862]
49. Fantuzzi G. Adipose tissue, adipokines, and inflammation. *J Allergy Clin Immunol.* 2005; 115:911–19. [PubMed: 15867843]
50. Fasshauer M, Bluher M, Stumvoll M, Tonessen P, Faber R, Stepan H. Differential regulation of visfatin and adiponectin in pregnancies with normal and abnormal placental function. *Clin Endocrinol (Oxf).* 2007; 66:434–39. [PubMed: 17302880]

51. Fasshauer M, Paschke R. Regulation of adipocytokines and insulin resistance. *Diabetologia*. 2003; 46:1594–603. [PubMed: 14605806]
52. Fasshauer M, Waldeyer T, Seeger J, Schrey S, Ebert T, Kratzsch J, et al. Serum levels of the adipokine visfatin are increased in preeclampsia. *Clin Endocrinol (Oxf)*. 2007
53. Fernandez-Real JM, Moreno JM, Chico B, Lopez-Bermejo A, Ricart W. Circulating visfatin is associated with parameters of iron metabolism in subjects with altered glucose tolerance. *Diabetes Care*. 2007; 30:616–21. [PubMed: 17327330]
54. Festa A, D'Agostino R Jr, Tracy RP, Haffner SM. Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes: the insulin resistance atherosclerosis study. *Diabetes*. 2002; 51:1131–37. [PubMed: 11916936]
55. Filippatos TD, Derdemezis CS, Gazi IF, Lagos K, Kiortsis DN, Tselepis AD, et al. Increased plasma visfatin levels in subjects with the metabolic syndrome. *Eur J Clin Invest*. 2008; 38:71–72. [PubMed: 18173555]
56. Filippatos TD, Derdemezis CS, Kiortsis DN, Tselepis AD, Elisaf MS. Increased plasma levels of visfatin/pre-B cell colony-enhancing factor in obese and overweight patients with metabolic syndrome. *J Endocrinol Invest*. 2007; 30:323–26. [PubMed: 17556870]
57. Filippi E, Sentinelli F, Trischitta V, Romeo S, Arca M, Leonetti F, et al. Association of the human adiponectin gene and insulin resistance. *Eur J Hum Genet*. 2004; 12:199–205. [PubMed: 14673476]
58. Fisher PM, Sutherland HW, Bewsher PD. The insulin response to glucose infusion in normal human pregnancy. *Diabetologia*. 1980; 19:15–20. [PubMed: 6993263]
59. Fruebis J, Tsao TS, Javorschi S, Ebbets-Reed D, Erickson MR, Yen FT, et al. Proteolytic cleavage product of 30-kDa adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice. *Proc Natl Acad Sci USA*. 2001; 98:2005–10. [PubMed: 11172066]
60. Frydelund-Larsen L, Akerstrom T, Nielsen S, Keller P, Keller C, Pedersen BK. Visfatin mRNA expression in human subcutaneous adipose tissue is regulated by exercise. *Am J Physiol Endocrinol Metab*. 2007; 292:E24–E31. [PubMed: 16868228]
61. Fujiki K, Shin DH, Nakao M, Yano T. Molecular cloning and expression analysis of the putative carp (*Cyprinus carpio*) pre-B cell enhancing factor. *Fish Shellfish Immunol*. 2000; 10:383–85. [PubMed: 10938748]
62. Fujinami A, Obayashi H, Ohta K, Ichimura T, Nishimura M, Matsui H, et al. Enzyme-linked immunosorbent assay for circulating human resistin: resistin concentrations in normal subjects and patients with type 2 diabetes. *Clin Chim Acta*. 2004; 339:57–63. [PubMed: 14687894]
63. Fukuhara A, Matsuda M, Nishizawa M, Segawa K, Tanaka M, Kishimoto K, et al. Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. *Science*. 2005; 307:426–30. [PubMed: 15604363]
64. Gabbe SG. Definition, detection, and management of gestational diabetes. *Obstet Gynecol*. 1986; 67:121–25. [PubMed: 3510012]
65. Gabbe SG. Gestational diabetes mellitus. *N Engl J Med*. 1986; 315:1025–26. [PubMed: 3762606]
66. Gabbe SG. Management of diabetes mellitus in pregnancy. *Am J Obstet Gynecol*. 1985; 153:824–28. [PubMed: 3907356]
67. Garg A. Adipose tissue dysfunction in obesity and lipodystrophy. *Clin Cornerstone*. 2006; 8 (Suppl 4):S7–S13. [PubMed: 17208666]
68. Gimeno RE, Klamann LD. Adipose tissue as an active endocrine organ: recent advances. *Curr Opin Pharmacol*. 2005; 5:122–28. [PubMed: 15780819]
69. Gonzalez RP, Gomez RM, Castro RS, Nien JK, Merino PO, Etchegaray AB, et al. A national birth weight distribution curve according to gestational age in Chile from 1993 to 2000. *Rev Med Chil*. 2004; 132:1155–65. [PubMed: 15631202]
70. Gonzalez-Sanchez JL, Zabena CA, Martinez-Larrad MT, Fernandez-Perez C, Perez-Barba M, Laakso M, et al. An SNP in the adiponectin gene is associated with decreased serum adiponectin levels and risk for impaired glucose tolerance. *Obes Res*. 2005; 13:807–12. [PubMed: 15919831]
71. Haider DG, Handisurya A, Storka A, Vojtassakova E, Luger A, Pacini G, et al. Visfatin response to glucose is reduced in women with gestational diabetes mellitus. *Diabetes Care*. 2007; 30:1889–91. [PubMed: 17416788]

72. Haider DG, Holzer G, Schaller G, Weghuber D, Widhalm K, Wagner O, et al. The adipokine visfatin is markedly elevated in obese children. *J Pediatr Gastroenterol Nutr.* 2006; 43:548–49. [PubMed: 17033537]
73. Haider DG, Schaller G, Kapiotis S, Maier C, Luger A, Wolzt M. The release of the adipocytokine visfatin is regulated by glucose and insulin. *Diabetologia.* 2006; 49:1909–14. [PubMed: 16736128]
74. Halaas JL, Gajiwala KS, Maffei M, Cohen SL, Chait BT, Rabinowitz D, et al. Weight-reducing effects of the plasma protein encoded by the obese gene. *Science.* 1995; 269:543–46. [PubMed: 7624777]
75. Hammarstedt A, Pihlajamäki J, Rotter SV, Gogg S, Jansson PA, Laakso M, et al. Visfatin is an adipokine, but it is not regulated by thiazolidinediones. *J Clin Endocrinol Metab.* 2006; 91:1181–84. [PubMed: 16394088]
76. Hara K, Boutin P, Mori Y, Tobe K, Dina C, Yasuda K, et al. Genetic variation in the gene encoding adiponectin is associated with an increased risk of type 2 diabetes in the Japanese population. *Diabetes.* 2002; 51:536–40. [PubMed: 11812766]
77. Havel PJ. Update on adipocyte hormones: regulation of energy balance and carbohydrate/lipid metabolism. *Diabetes.* 2004; 53 (Suppl 1):S143–S151. [PubMed: 14749280]
78. Hotamisligil GS. Inflammation and metabolic disorders. *Nature.* 2006; 444:860–67. [PubMed: 17167474]
79. Hotta K, Funahashi T, Arita Y, Takahashi M, Matsuda M, Okamoto Y, et al. Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. *Arterioscler Thromb Vasc Biol.* 2000; 20:1595–99. [PubMed: 10845877]
80. Houseknecht KL, Portocarrero CP. Leptin and its receptors: regulators of whole-body energy homeostasis. *Domest Anim Endocrinol.* 1998; 15:457–75. [PubMed: 9861538]
81. Hu FB, Doria A, Li T, Meigs JB, Liu S, Memisoglu A, et al. Genetic variation at the adiponectin locus and risk of type 2 diabetes in women. *Diabetes.* 2004; 53:209–13. [PubMed: 14693717]
82. Hug C, Lodish HF. Medicine. Visfatin: a new adipokine. *Science.* 2005; 307:366–67. [PubMed: 15604359]
83. Hutley L, Prins JB. Fat as an endocrine organ: relationship to the metabolic syndrome. *Am J Med Sci.* 2005; 330:280–89. [PubMed: 16355012]
84. Iqbal J, Zaidi M. TNF regulates cellular NAD⁺ metabolism in primary macrophages. *Biochem Biophys Res Commun.* 2006; 342:1312–18. [PubMed: 16516847]
85. Jensen DM, Sorensen B, Feilberg-Jorgensen N, Westergaard JG, Beck-Nielsen H. Maternal and perinatal outcomes in 143 Danish women with gestational diabetes mellitus and 143 controls with a similar risk profile. *Diabet Med.* 2000; 17:281–86. [PubMed: 10821294]
86. Jia SH, Li Y, Parodo J, Kapus A, Fan L, Rotstein OD, et al. Pre-B cell colony-enhancing factor inhibits neutrophil apoptosis in experimental inflammation and clinical sepsis. *J Clin Invest.* 2004; 113:1318–27. [PubMed: 15124023]
87. Jin H, Jiang B, Tang J, Lu W, Wang W, Zhou L, et al. Serum visfatin concentrations in obese adolescents and its correlation with age and high-density lipoprotein cholesterol. *Diabetes Res Clin Pract.* 2008; 79:412–418. [PubMed: 18241953]
88. Kahn BB, Flier JS. Obesity and insulin resistance. *J Clin Invest.* 2000; 106:473–81. [PubMed: 10953022]
89. Kahn SE, Hull RL, Utzschneider KM. Mechanisms linking obesity to insulin resistance and type 2 diabetes. *Nature.* 2006; 444:840–46. [PubMed: 17167471]
90. Kalkhoff RK, Jacobson M, Lemper D. Progesterone, pregnancy and the augmented plasma insulin response. *J Clin Endocrinol Metab.* 1970; 31:24–28. [PubMed: 4316582]
91. Kalkhoff RK, Richardson BL, Beck P. Relative effects of pregnancy, human placental lactogen and prednisolone on carbohydrate tolerance in normal and subclinical diabetic subjects. *Diabetes.* 1969; 18:153–63. [PubMed: 5386597]
92. Kaufmann RC, McBride P, Amankwah KS, Huffman DG. The effect of minor degrees of glucose intolerance on the incidence of neonatal macrosomia. *Obstet Gynecol.* 1992; 80:97–101. [PubMed: 1603507]
93. Kautzky-Willer A, Pacini G, Tura A, Biegelmayer C, Schneider B, Ludvik B, et al. Increased plasma leptin in gestational diabetes. *Diabetologia.* 2001; 44:164–72. [PubMed: 11270672]

94. Kendal-Wright CE. Stretching, mechanotransduction, and proinflammatory cytokines in the fetal membranes. *Reprod Sci.* 2007; 14:35–41. [PubMed: 18089608]
95. Kendal-Wright CE, Hubbard D, Bryant-Greenwood GD. Chronic Stretching of Amniotic Epithelial Cells Increases Pre-B Cell Colony-Enhancing Factor (PBEF/Visfatin) Expression and Protects Them from Apoptosis. *Placenta.* 2008; 29:255–265. [PubMed: 18272217]
96. Kim C, Newton KM, Knopp RH. Gestational diabetes and the incidence of type 2 diabetes: a systematic review. *Diabetes Care.* 2002; 25:1862–68. [PubMed: 12351492]
97. Kim MJ, Yoo KH, Park HS, Chung SM, Jin CJ, Lee Y, et al. Plasma adiponectin and insulin resistance in Korean type 2 diabetes mellitus. *Yonsei Med J.* 2005; 46:42–50. [PubMed: 15744804]
98. Kinalski M, Telejko B, Kuzmicki M, Kretowski A, Kinalska I. Tumor necrosis factor alpha system and plasma adiponectin concentration in women with gestational diabetes. *Horm Metab Res.* 2005; 37:450–54. [PubMed: 16034719]
99. Kirwan JP, Hauguel-De MS, Lepercq J, Challier JC, Huston-Presley L, Friedman JE, et al. TNF-alpha is a predictor of insulin resistance in human pregnancy. *Diabetes.* 2002; 51:2207–13. [PubMed: 12086951]
100. Kjos SL, Peters RK, Xiang A, Henry OA, Montoro M, Buchanan TA. Predicting future diabetes in Latino women with gestational diabetes. Utility of early postpartum glucose tolerance testing. *Diabetes.* 1995; 44:586–91. [PubMed: 7729620]
101. Krzyzanowska K, Krugluger W, Mittermayer F, Rahman R, Haider D, Shnawa N, et al. Increased visfatin concentrations in women with gestational diabetes mellitus. *Clin Sci(Lond).* 2006; 110:605–09. [PubMed: 16489932]
102. Krzyzanowska K, Mittermayer F, Krugluger W, Kopp HP, Schernthaner G. Increase in visfatin after weight loss induced by gastroplastic surgery. *Obesity (Silver Spring).* 2006; 14:1886–89. [PubMed: 17135602]
103. Kubota N, Terauchi Y, Yamauchi T, Kubota T, Moroi M, Matsui J, et al. Disruption of adiponectin causes insulin resistance and neointimal formation. *J Biol Chem.* 2002; 277:25863–66. [PubMed: 12032136]
104. Kuhl C. Aetiology of gestational diabetes. *Baillieres Clin Obstet Gynaecol.* 1991; 5:279–92. [PubMed: 1954714]
105. Kuhl C. Glucose metabolism during and after pregnancy in normal and gestational diabetic women. 1. Influence of normal pregnancy on serum glucose and insulin concentration during basal fasting conditions and after a challenge with glucose. *Acta Endocrinol(Copenh).* 1975; 79:709–19. [PubMed: 1173969]
106. Laclaustra M, Corella D, Ordovas JM. Metabolic syndrome pathophysiology: the role of adipose tissue. *Nutr Metab Cardiovasc Dis.* 2007; 17:125–39. [PubMed: 17270403]
107. Lago F, Dieguez C, Gomez-Reino J, Gualillo O. The emerging role of adipokines as mediators of inflammation and immune responses. *Cytokine Growth Factor Rev.* 2007; 18:313–25. [PubMed: 17507280]
108. Langer O, Anyaegbunam A, Brustman L, Divon M. Management of women with one abnormal oral glucose tolerance test value reduces adverse outcome in pregnancy. *Am J Obstet Gynecol.* 1989; 161:593–99. [PubMed: 2675597]
109. Langer O, Anyaegbunam A, Brustman L, Guidetti D, Mazze R. Gestational diabetes: insulin requirements in pregnancy. *Am J Obstet Gynecol.* 1987; 157:669–75. [PubMed: 3307425]
110. Lee YY, Lee NS, Cho YM, Moon MK, Jung HS, Park YJ, et al. Genetic association study of adiponectin polymorphisms with risk of Type 2 diabetes mellitus in Korean population. *Diabet Med.* 2005; 22:569–75. [PubMed: 15842511]
111. Leikin EL, Jenkins JH, Pomerantz GA, Klein L. Abnormal glucose screening tests in pregnancy: a risk factor for fetal macrosomia. *Obstet Gynecol.* 1987; 69:570–73. [PubMed: 3822298]
112. Lewandowski KC, Stojanovic N, Press M, Tuck SM, Szosland K, Bienkiewicz M, et al. Elevated serum levels of visfatin in gestational diabetes: a comparative study across various degrees of glucose tolerance. *Diabetologia.* 2007; 50:1033–37. [PubMed: 17334748]

113. Li L, Yang G, Li Q, Tang Y, Yang M, Yang H, et al. Changes and relations of circulating visfatin, apelin, and resistin levels in normal, impaired glucose tolerance, and type 2 diabetic subjects. *Exp Clin Endocrinol Diabetes*. 2006; 114:544–48. [PubMed: 17177135]
114. Lind T, Bell S, Gilmore E, Huisjes HJ, Schally AV. Insulin disappearance rate in pregnant and non-pregnant women, and in non-pregnant women given GHRIH. *Eur J Clin Invest*. 1977; 7:47–52. [PubMed: 402276]
115. Lindsay MK, Graves W, Klein L. The relationship of one abnormal glucose tolerance test value and pregnancy complications. *Obstet Gynecol*. 1989; 73:103–06. [PubMed: 2909030]
116. Lopez-Bermejo A, Chico-Julia B, Fernandez-Balsells M, Recasens M, Esteve E, Casamitjana R, et al. Serum visfatin increases with progressive beta-cell deterioration. *Diabetes*. 2006; 55:2871–75. [PubMed: 17003355]
117. Lopez-Bermejo A, de ZF, az-Silva M, Vicente MP, Valls C, Ibanez L. Cord serum visfatin at term birth: maternal smoking unmasks the relation to foetal growth. *Clin Endocrinol(Oxf)*. 2008; 68:77–81. [PubMed: 17681025]
118. Lopez-Bermejo A, Fernandez-Real JM, Garrido E, Rovira R, Brichs R, Genaro P, et al. Maternal soluble tumour necrosis factor receptor type 2 (sTNFR2) and adiponectin are both related to blood pressure during gestation and infant's birthweight. *Clin Endocrinol(Oxf)*. 2004; 61:544–52. [PubMed: 15521955]
119. Maeda N, Shimomura I, Kishida K, Nishizawa H, Matsuda M, Nagaretani H, et al. Diet-induced insulin resistance in mice lacking adiponectin/ACRP30. *Nat Med*. 2002; 8:731–37. [PubMed: 12068289]
120. Malamitsi-Puchner A, Briana DD, Boutsikou M, Kouskouni E, Hassiakos D, Gourgiotis D. Perinatal circulating visfatin levels in intrauterine growth restriction. *Pediatrics*. 2007; 119:e1314–e1318. [PubMed: 17502346]
121. Malamitsi-Puchner A, Briana DD, Gourgiotis D, Boutsikou M, Baka S, Hassiakos D. Blood visfatin concentrations in normal full-term pregnancies. *Acta Paediatr*. 2007; 96:526–29. [PubMed: 17391471]
122. Manco M, Fernandez-Real JM, Equitani F, Vendrell J, Valera Mora ME, Nanni G, et al. Effect of massive weight loss on inflammatory adipocytokines and the innate immune system in morbidly obese women. *J Clin Endocrinol Metab*. 2007; 92:483–90. [PubMed: 17105839]
123. Martin PR, Shea RJ, Mulks MH. Identification of a plasmid-encoded gene from *Haemophilus ducreyi* which confers NAD independence. *J Bacteriol*. 2001; 183:1168–74. [PubMed: 11157928]
124. Marvin KW, Keelan JA, Eykholt RL, Sato TA, Mitchell MD. Use of cDNA arrays to generate differential expression profiles for inflammatory genes in human gestational membranes delivered at term and preterm. *Mol Hum Reprod*. 2002; 8:399–408. [PubMed: 11912289]
125. Mastorakos G, Valsamakis G, Papatheodorou DC, Barlas I, Margeli A, Boutsiadis A, et al. The role of adipocytokines in insulin resistance in normal pregnancy: visfatin concentrations in early pregnancy predict insulin sensitivity. *Clin Chem*. 2007; 53:1477–83. [PubMed: 17586594]
126. Matsuzawa Y, Funahashi T, Nakamura T. Molecular mechanism of metabolic syndrome X: contribution of adipocytokines adipocyte-derived bioactive substances. *Ann NY Acad Sci*. 1999; 892:146–54. [PubMed: 10842660]
127. McGlothlin JR, Gao L, Lavoie T, Simon BA, Easley RB, Ma SF, et al. Molecular cloning and characterization of canine pre-B-cell colony-enhancing factor. *Biochem Genet*. 2005; 43:127–41. [PubMed: 15934174]
128. McLachlan KA, O'Neal D, Jenkins A, Alford FP. Do adiponectin, TNFalpha, leptin and CRP relate to insulin resistance in pregnancy? Studies in women with and without gestational diabetes, during and after pregnancy. *Diabetes Metab Res Rev*. 2006; 22:131–38. [PubMed: 16170833]
129. McTernan PG, Fisher FM, Valsamakis G, Chetty R, Harte A, McTernan CL, et al. Resistin and type 2 diabetes: regulation of resistin expression by insulin and rosiglitazone and the effects of recombinant resistin on lipid and glucose metabolism in human differentiated adipocytes. *J Clin Endocrinol Metab*. 2003; 88:6098–106. [PubMed: 14671216]

130. Mello G, Parretti E, Mecacci F, Lucchetti R, Lagazio C, Pratesi M, et al. Risk factors for fetal macrosomia: the importance of a positive oral glucose challenge test. *Eur J Endocrinol.* 1997; 137:27–33. [PubMed: 9242198]
131. Menzaghi C, Coco A, Salvemini L, Thompson R, De CS, Doria A, et al. Heritability of serum resistin and its genetic correlation with insulin resistance-related features in nondiabetic Caucasians. *J Clin Endocrinol Metab.* 2006; 91:2792–95. [PubMed: 16670163]
132. Menzaghi C, Ercolino T, Di PR, Berg AH, Warram JH, Scherer PE, et al. A haplotype at the adiponectin locus is associated with obesity and other features of the insulin resistance syndrome. *Diabetes.* 2002; 51:2306–12. [PubMed: 12086965]
133. Metzger BE, Cho NH, Roston SM, Radvany R. Prepregnancy weight and antepartum insulin secretion predict glucose tolerance five years after gestational diabetes mellitus. *Diabetes Care.* 1993; 16:1598–605. [PubMed: 8299456]
134. Metzger BE, Coustan DR. Summary and recommendations of the Fourth International Workshop-Conference on Gestational Diabetes Mellitus. The Organizing Committee *Diabetes Care.* 1998; 21 (Suppl 2):B161–B167.
135. Mishima Y, Kuyama A, Tada A, Takahashi K, Ishioka T, Kibata M. Relationship between serum tumor necrosis factor-alpha and insulin resistance in obese men with Type 2 diabetes mellitus. *Diabetes Res Clin Pract.* 2001; 52:119–23. [PubMed: 11311966]
136. Montague CT, O’Rahilly S. The perils of portliness: causes and consequences of visceral adiposity. *Diabetes.* 2000; 49:883–88. [PubMed: 10866038]
137. Moschen AR, Kaser A, Enrich B, Mosheimer B, Theurl M, Niederegger H, et al. Visfatin, an adipocytokine with proinflammatory and immunomodulating properties. *J Immunol.* 2007; 178:1748–58. [PubMed: 17237424]
138. Muller WE, Perovic S, Wilkesman J, Kruse M, Muller IM, Batel R. Increased gene expression of a cytokine-related molecule and profilin after activation of Suberites domuncula cells with xenogeneic sponge molecule(s). *DNA Cell Biol.* 1999; 18:885–93. [PubMed: 10619600]
139. Nakatani K, Noma K, Nishioka J, Kasai Y, Morioka K, Katsuki A, et al. Adiponectin gene variation associates with the increasing risk of type 2 diabetes in non-diabetic Japanese subjects. *Int J Mol Med.* 2005; 15:173–77. [PubMed: 15583845]
140. Nawrocki AR, Rajala MW, Tomas E, Pajvani UB, Saha AK, Trumbauer ME, et al. Mice lacking adiponectin show decreased hepatic insulin sensitivity and reduced responsiveness to peroxisome proliferator-activated receptor gamma agonists. *J Biol Chem.* 2006; 281:2654–60. [PubMed: 16326714]
141. Naylor CD, Sermer M, Chen E, Sykora K. Cesarean delivery in relation to birth weight and gestational glucose tolerance: pathophysiology or practice style? Toronto Trihospital Gestational Diabetes Investigators *JAMA.* 1996; 275:1165–70.
142. Nemeth E, Millar LK, Bryant-Greenwood G. Fetal membrane distention: II. Differentially expressed genes regulated by acute distention in vitro. *Am J Obstet Gynecol.* 2000; 182:60–67. [PubMed: 10649157]
143. Nemeth E, Tashima LS, Yu Z, Bryant-Greenwood GD. Fetal membrane distention: I. Differentially expressed genes regulated by acute distention in amniotic epithelial (WISH) cells. *Am J Obstet Gynecol.* 2000; 182:50–59. [PubMed: 10649156]
144. Nowell MA, Richards PJ, Fielding CA, Ognjanovic S, Topley N, Williams AS, et al. Regulation of pre-B cell colony-enhancing factor by STAT-3-dependent interleukin-6 trans-signaling: implications in the pathogenesis of rheumatoid arthritis. *Arthritis Rheum.* 2006; 54:2084–95. [PubMed: 16802343]
145. O’Sullivan JB. Diabetes mellitus after GDM. *Diabetes.* 1991; 40 (Suppl 2):131–35. [PubMed: 1748242]
146. O’Sullivan JB, Charles D, MAHAN CM, Dandrow RV. Gestational diabetes and perinatal mortality rate. *Am J Obstet Gynecol.* 1973; 116:901–04. [PubMed: 4718217]
147. O’Sullivan JB, MAHAN CM. CRITERIA FOR THE ORAL GLUCOSE TOLERANCE TEST IN PREGNANCY. *Diabetes.* 1964; 13:278–85. [PubMed: 14166677]

148. Ognjanovic S, Bao S, Yamamoto SY, Garibay-Tupas J, Samal B, Bryant-Greenwood GD. Genomic organization of the gene coding for human pre-B-cell colony enhancing factor and expression in human fetal membranes. *J Mol Endocrinol*. 2001; 26:107–17. [PubMed: 11241162]
149. Ognjanovic S, Bryant-Greenwood GD. Pre-B-cell colony-enhancing factor, a novel cytokine of human fetal membranes. *Am J Obstet Gynecol*. 2002; 187:1051–58. [PubMed: 12389004]
150. Ognjanovic S, Ku TL, Bryant-Greenwood GD. Pre-B-cell colony-enhancing factor is a secreted cytokine-like protein from the human amniotic epithelium. *Am J Obstet Gynecol*. 2005; 193:273–82. [PubMed: 16021090]
151. Ognjanovic S, Tashima LS, Bryant-Greenwood GD. The effects of pre-B-cell colony-enhancing factor on the human fetal membranes by microarray analysis. *Am J Obstet Gynecol*. 2003; 189:1187–95. [PubMed: 14586377]
152. Osawa H, Yamada K, Onuma H, Murakami A, Ochi M, Kawata H, et al. The G/G genotype of a resistin single-nucleotide polymorphism at -420 increases type 2 diabetes mellitus susceptibility by inducing promoter activity through specific binding of Sp1/3. *Am J Hum Genet*. 2004; 75:678–86. [PubMed: 15338456]
153. Otero M, Lago R, Gomez R, Lago F, Dieguez C, Gomez-Reino JJ, et al. Changes in plasma levels of fat-derived hormones adiponectin, leptin, resistin and visfatin in patients with rheumatoid arthritis. *Ann Rheum Dis*. 2006; 65:1198–201. [PubMed: 16414972]
154. Ouchi N, Kihara S, Arita Y, Okamoto Y, Maeda K, Kuriyama H, et al. Adiponectin, an adipocyte-derived plasma protein, inhibits endothelial NF-kappaB signaling through a cAMP-dependent pathway. *Circulation*. 2000; 102:1296–301. [PubMed: 10982546]
155. Pajvani UB, Scherer PE. Adiponectin: systemic contributor to insulin sensitivity. *Curr Diab Rep*. 2003; 3:207–13. [PubMed: 12762967]
156. Pelleymounter MA, Cullen MJ, Baker MB, Hecht R, Winters D, Boone T, et al. Effects of the obese gene product on body weight regulation in ob/ob mice. *Science*. 1995; 269:540–43. [PubMed: 7624776]
157. Pettitt DJ, Knowler WC, Baird HR, Bennett PH. Gestational diabetes: infant and maternal complications of pregnancy in relation to third-trimester glucose tolerance in the Pima Indians. *Diabetes Care*. 1980; 3:458–64. [PubMed: 7389563]
158. Phelps RL, Metzger BE, Freinkel N. Carbohydrate metabolism in pregnancy. XVII. Diurnal profiles of plasma glucose, insulin, free fatty acids, triglycerides, cholesterol, and individual amino acids in late normal pregnancy. *Am J Obstet Gynecol*. 1981; 140:730–36. [PubMed: 7020420]
159. Polderman KH, Gooren LJ, Asscheman H, Bakker A, Heine RJ. Induction of insulin resistance by androgens and estrogens. *J Clin Endocrinol Metab*. 1994; 79:265–71. [PubMed: 8027240]
160. Putz DM, Goldner WS, Bar RS, Haynes WG, Sivitz WI. Adiponectin and C-reactive protein in obesity, type 2 diabetes, and monodrug therapy. *Metabolism*. 2004; 53:1454–61. [PubMed: 15536601]
161. Rajala MW, Scherer PE. Minireview: The adipocyte--at the crossroads of energy homeostasis, inflammation, and atherosclerosis. *Endocrinology*. 2003; 144:3765–73. [PubMed: 12933646]
162. Ranheim T, Haugen F, Staff AC, Braekke K, Harsem NK, Drevon CA. Adiponectin is reduced in gestational diabetes mellitus in normal weight women. *Acta Obstet Gynecol Scand*. 2004; 83:341–47. [PubMed: 15005780]
163. Retnakaran R, Hanley AJ, Raif N, Connelly PW, Sermer M, Zinman B. Reduced adiponectin concentration in women with gestational diabetes: a potential factor in progression to type 2 diabetes. *Diabetes Care*. 2004; 27:799–800. [PubMed: 14988306]
164. Ronti T, Lupattelli G, Mannarino E. The endocrine function of adipose tissue: an update. *Clin Endocrinol(Oxf)*. 2006; 64:355–65. [PubMed: 16584505]
165. Ryan EA. Hormones and insulin resistance during pregnancy. *Lancet*. 2003; 362:1777–78. [PubMed: 14654313]
166. Ryan EA, Enns L. Role of gestational hormones in the induction of insulin resistance. *J Clin Endocrinol Metab*. 1988; 67:341–47. [PubMed: 3292560]
167. Ryan EA, O'Sullivan MJ, Skyler JS. Insulin action during pregnancy. Studies with the euglycemic clamp technique. *Diabetes*. 1985; 34:380–89. [PubMed: 3882502]

168. Salopuro T, Pulkkinen L, Lindstrom J, Eriksson JG, Valle TT, Hamalainen H, et al. Genetic variation in leptin receptor gene is associated with type 2 diabetes and body weight: The Finnish Diabetes Prevention Study. *Int J Obes(Lond)*. 2005; 29:1245–51. [PubMed: 15997246]
169. Samaan N, Yen SC, Gonzalez D, Pearson OH. Metabolic effects of placental lactogen (HPL) in man. *J Clin Endocrinol Metab*. 1968; 28:485–91. [PubMed: 5643868]
170. Samal B, Sun Y, Stearns G, Xie C, Suggs S, McNiece I. Cloning and characterization of the cDNA encoding a novel human pre-B-cell colony-enhancing factor. *Mol Cell Biol*. 1994; 14:1431–37. [PubMed: 8289818]
171. Sandeep S, Velmurugan K, Deepa R, Mohan V. Serum visfatin in relation to visceral fat, obesity, and type 2 diabetes mellitus in Asian Indians. *Metabolism*. 2007; 56:565–70. [PubMed: 17379018]
172. Scott DA, Loveman E, McIntyre L, Waugh N. Screening for gestational diabetes: a systematic review and economic evaluation. *Health Technol Assess*. 2002; 6:1–161. [PubMed: 12433317]
173. Sethi JK. Is PBEF/visfatin/Nampt an authentic adipokine relevant to the metabolic syndrome? *Curr Hypertens Rep*. 2007; 9:33–38. [PubMed: 17362669]
174. Sethi JK, Vidal-Puig A. Visfatin: the missing link between intra-abdominal obesity and diabetes? *Trends Mol. Med*. 2005; 11:344–47.
175. Shea J, Randell E, Vasdev S, Wang PP, Roebothan B, Sun G. Serum retinol-binding protein 4 concentrations in response to short-term overfeeding in normal-weight, overweight, and obese men. *Am J Clin Nutr*. 2007; 86:1310–15. [PubMed: 17991640]
176. Smirnakis KV, Plati A, Wolf M, Thadhani R, Ecker JL. Predicting gestational diabetes: choosing the optimal early serum marker. *Am J Obstet Gynecol*. 2007; 196:410–16. [PubMed: 17403439]
177. SPELLACY WN, GOETZ FC, GREENBERG BZ, ELLS J. PLASMA INSULIN IN NORMAL “EARLY” PREGNANCY. *Obstet Gynecol*. 1965; 25:862–65. [PubMed: 14287481]
178. Spiegelman BM, Flier JS. Obesity and the regulation of energy balance. *Cell*. 2001; 104:531–43. [PubMed: 11239410]
179. Steinhart JR, Sugarman JR, Connell FA. Gestational diabetes is a herald of NIDDM in Navajo women. High rate of abnormal glucose tolerance after GDM. *Diabetes Care*. 1997; 20:943–47. [PubMed: 9167104]
180. Stephenson MJ. Screening for gestational diabetes mellitus: a critical review. *J Fam Pract*. 1993; 37:277–83. [PubMed: 8409879]
181. Steppan CM, Bailey ST, Bhat S, Brown EJ, Banerjee RR, Wright CM, et al. The hormone resistin links obesity to diabetes. *Nature*. 2001; 409:307–12. [PubMed: 11201732]
182. Stumvoll M, Tschritter O, Fritsche A, Staiger H, Renn W, Weisser M, et al. Association of the T-G polymorphism in adiponectin (exon 2) with obesity and insulin sensitivity: interaction with family history of type 2 diabetes. *Diabetes*. 2002; 51:37–41. [PubMed: 11756320]
183. Tan BK, Chen J, Digby JE, Keay SD, Kennedy CR, Randeve HS. Increased visfatin messenger ribonucleic acid and protein levels in adipose tissue and adipocytes in women with polycystic ovary syndrome: parallel increase in plasma visfatin. *J Clin Endocrinol Metab*. 2006; 91:5022–28. [PubMed: 17003086]
184. Tanaka M, Nozaki M, Fukuhara A, Segawa K, Aoki N, Matsuda M, et al. Visfatin is released from 3T3-L1 adipocytes via a non-classical pathway. *Biochem Biophys Res Commun*. 2007; 359:194–201. [PubMed: 17543285]
185. Thyfault JP, Hedberg EM, Anchan RM, Thorne OP, Isler CM, Newton ER, et al. Gestational diabetes is associated with depressed adiponectin levels. *J Soc Gynecol Investig*. 2005; 12:41–45.
186. Tilg H, Moschen AR. Adipocytokines: mediators linking adipose tissue, inflammation and immunity. *Nat Rev Immunol*. 2006; 6:772–83. [PubMed: 16998510]
187. Trayhurn P. Endocrine and signalling role of adipose tissue: new perspectives on fat. *Acta Physiol Scand*. 2005; 184:285–93. [PubMed: 16026420]
188. Tsiotra PC, Tsigos C, Yfanti E, Anastasiou E, Vikentiou M, Psarra K, et al. Visfatin, TNF-alpha and IL-6 mRNA expression is increased in mononuclear cells from type 2 diabetic women. *Horm Metab Res*. 2007; 39:758–63. [PubMed: 17952840]

189. Ventre J, Doebber T, Wu M, MacNaul K, Stevens K, Pasparakis M, et al. Targeted disruption of the tumor necrosis factor- α gene: metabolic consequences in obese and nonobese mice. *Diabetes*. 1997; 46:1526–31. [PubMed: 9287059]
190. Wellen KE, Hotamisligil GS. Inflammation, stress, and diabetes. *J Clin Invest*. 2005; 115:1111–19. [PubMed: 15864338]
191. Weyer C, Funahashi T, Tanaka S, Hotta K, Matsuzawa Y, Pratley RE, et al. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. *J Clin Endocrinol Metab*. 2001; 86:1930–35. [PubMed: 11344187]
192. Williams MA, Qiu C, Muy-Rivera M, Vadachkoria S, Song T, Luthy DA. Plasma adiponectin concentrations in early pregnancy and subsequent risk of gestational diabetes mellitus. *J Clin Endocrinol Metab*. 2004; 89:2306–11. [PubMed: 15126557]
193. Wolf M, Sandler L, Hsu K, Vossen-Smirnakis K, Ecker JL, Thadhani R. First-trimester C-reactive protein and subsequent gestational diabetes. *Diabetes Care*. 2003; 26:819–24. [PubMed: 12610043]
194. Worda C, Leipold H, Gruber C, Kautzky-Willer A, Knofler M, Bancher-Todesca D. Decreased plasma adiponectin concentrations in women with gestational diabetes mellitus. *Am J Obstet Gynecol*. 2004; 191:2120–24. [PubMed: 15592301]
195. Xie H, Tang SY, Luo XH, Huang J, Cui RR, Yuan LQ, et al. Insulin-like effects of visfatin on human osteoblasts. *Calcif Tissue Int*. 2007; 80:201–10. [PubMed: 17340225]
196. Yamauchi T, Kamon J, Waki H, Terauchi Y, Kubota N, Hara K, et al. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. *Nat Med*. 2001; 7:941–46. [PubMed: 11479627]
197. Yang Q, Graham TE, Mody N, Preitner F, Peroni OD, Zabolotny JM, et al. Serum retinol binding protein 4 contributes to insulin resistance in obesity and type 2 diabetes. *Nature*. 2005; 436:356–62. [PubMed: 16034410]
198. Ye SQ, Simon BA, Maloney JP, Zambelli-Weiner A, Gao L, Grant A, et al. Pre-B-cell colony-enhancing factor as a potential novel biomarker in acute lung injury. *Am J Respir Crit Care Med*. 2005; 171:361–70. [PubMed: 15579727]
199. Ye SQ, Zhang LQ, Adyshev D, Usatyuk PV, Garcia AN, Lavoie TL, et al. Pre-B-cell-colony-enhancing factor is critically involved in thrombin-induced lung endothelial cell barrier dysregulation. *Microvasc Res*. 2005; 70:142–51. [PubMed: 16188281]
200. Yogev Y, Langer O, Xenakis EM, Rosenn B. The association between glucose challenge test, obesity and pregnancy outcome in 6390 non-diabetic women. *J Matern Fetal Neonatal Med*. 2005; 17:29–34. [PubMed: 15804783]
201. Yokota T, Oritani K, Takahashi I, Ishikawa J, Matsuyama A, Ouchi N, et al. Adiponectin, a new member of the family of soluble defense collagens, negatively regulates the growth of myelomonocytic progenitors and the functions of macrophages. *Blood*. 2000; 96:1723–32. [PubMed: 10961870]
202. Youn BS, Yu KY, Park HJ, Lee NS, Min SS, Youn MY, et al. Plasma resistin concentrations measured by enzyme-linked immunosorbent assay using a newly developed monoclonal antibody are elevated in individuals with type 2 diabetes mellitus. *J Clin Endocrinol Metab*. 2004; 89:150–56. [PubMed: 14715842]
203. Zahorska-Markiewicz B, Olszanecka-Glinianowicz M, Janowska J, Kocelak P, Semik-Grabarczyk E, Holecki M, et al. Serum concentration of visfatin in obese women. *Metabolism*. 2007; 56:1131–34. [PubMed: 17618961]
204. Zhang YY, Gottardo L, Thompson R, Powers C, Nolan D, Duffy J, et al. A visfatin promoter polymorphism is associated with low-grade inflammation and type 2 diabetes. *Obesity (Silver Spring)*. 2006; 14:2119–26. [PubMed: 17189536]

Figure 1. Comparison of the median maternal plasma visfatin concentrations between women with and without GDM and/or an LGA fetus

The median maternal plasma visfatin concentration was higher in patients with GDM, either with an AGA or with LGA fetus, than that of those with a normal pregnancy and an AGA fetus. Likewise, pregnant women with a normal pregnancy and an LGA fetus had a higher median maternal plasma visfatin concentration than those with a normal pregnancy and an AGA fetus.

Figure 2. Comparison of the median maternal plasma visfatin concentrations between normal and overweight/obese pregnant women, with and without GDM and/or an LGA fetus

Among overweight/obese patients, the median maternal plasma visfatin concentration was significantly higher in patients with GDM, either with an AGA or with LGA fetus, than that of those with a normal pregnancy and an AGA fetus. Likewise, overweight/obese pregnant women with a normal pregnancy and an LGA fetus had a higher median maternal plasma visfatin concentration than those with a normal pregnancy and an AGA fetus. In contrast, there was no significant difference in the median maternal plasma visfatin concentration among pregnant women with normal weight. Within each study group, the median maternal plasma visfatin concentration was comparable between normal and overweight/obese pregnant women.

Table 1

Clinical and demographic characteristics of the study population

	Normal pregnancy AGA neonate (n = 54)	Normal pregnancy LGA neonate (n = 47)	GDM AGA neonate (n = 56)	GDM LGA neonate (n = 45)
Maternal age (years) [*], #	27 (22–30)	28 (22–32)	32 (24–36)	30 (25–35)
BMI (kg/m²) [*], #, \$	23 (22–25)	24 (22–28)	26 (22–29)	27 (23–32)
BMI 25[#]	17 (31.4%)	21 (44.6%)	36 (64.2%)	30 (66.6%)
Gestational age at blood sampling (weeks)	39 (38–40)	39 (38–40)	38 (38–40)	38 (38–39)
Gestational age at delivery (weeks)	39 (38–40)	39 (38–40)	39 (38–40)	38 (38–39)
Birth weight (g) ^{#, &, \$, ‡}	3390 (3150–3612)	4170 (4050–4415)	3455 (3235–3717)	4190 (4030–4410)

^{*}p<0.05 – Normal pregnancy+AGA vs. GDM+AGA

[#]p<0.05 – Normal pregnancy+AGA vs. GDM+LGA

^{\$}p<0.05 – Normal pregnancy+LGA vs. GDM+LGA

[&]p<0.05 – Normal pregnancy+AGA vs. Normal pregnancy+LGA

^{\$}p<0.05 – GDM+AGA vs. Normal pregnancy+LGA

[‡]p<0.05 – GDM+AGA vs. GDM+LGA

Values are expressed as median (IQR) or as number (percentage); AGA – Appropriate for gestational age; LGA – Large for gestational age; GDM – Gestational Diabetes Mellitus; BMI – Body Mass Index

Table 2

Linear regression analysis of factors associated with maternal plasma visfatin concentrations

Factor	Beta	Significance
Delivery of LGA neonate	0.193	0.008
GDM	0.174	0.032
Maternal BMI	−0.120	0.115
Gestational age at blood collection	0.106	0.154
Maternal age	0.027	0.728

LGA: large for gestational age; GDM: gestational diabetes mellitus; BMI: body mass index